|
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer Clinical research trials and Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer. Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer  Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
For Condition: recurrent endometrial cancer
Status: Recruiting
Sponsor(s): Gynecologic Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have persistent or recurrentendometrial cancer.
Details: OBJECTIVES: - Determine the antitumor activity of oxaliplatin in terms of response rate in patients with persistent or recurrent endometrial carcinoma that is refractory to curative or established therapy. - Determine the nature and degree of toxicity of this treatment regimen in these patients. OUTLINE: This is a multicenter study. Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed endometrial carcinoma that is refractory to curative therapy or established treatment - Clinically and/or histologically confirmed persistent or recurrent disease - Measurable disease by physical examination or medical imaging - Sonography allowed if lesions are clearly defined on initial examination and bidimensionally measurable - Ascites or pleural effusions not considered measurable - Must have received 1 prior cytotoxic therapy regimen - May include high-dose therapy, consolidation, or extended therapy after surgical or nonsurgical assessment - 1 additional noncytotoxic regimen allowed - Biologic or cytostatic agents include, but are not limited to: - Monoclonal antibodies - Cytokines - Small-molecule inhibitors of signal transduction - Ineligible for a higher priority GOG protocol - No known brain metastases PATIENT CHARACTERISTICS: Age - Any age Performance status - GOG 0-2 if received 1 prior therapy regimen - GOG 0-1 if received 2 prior therapy regimens Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT no greater than 2.5 times ULN - Alkaline phosphatase no greater than 2.5 times ULN Renal - Creatinine no greater than 1.5 times ULN Cardiovascular - No symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia Neurologic - No sensory or motor neuropathy greater than grade 1 - No residual neuropathy attributed to prior chemotherapy or other chronic conditions (e.g., diabetes, venous stasis, or carpal tunnel syndrome) Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergy to platinum compounds or antiemetics - No active infection requiring antibiotics - No other uncontrolled illness - No other invasive malignancies within the past 5 years except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 14 days since prior pegfilgrastim - At least 24 hours since other prior growth factors - At least 3 weeks since prior biologic or immunologic therapy - No concurrent growth factors during first course of study therapy Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered - No more than 1 prior cytotoxic chemotherapy regimen, either single or combination cytotoxic drug therapy - No prior oxaliplatin Endocrine therapy - At least 1 week since prior hormonal therapy directed at tumor - Concurrent hormone replacement therapy allowed Radiotherapy - At least 4 weeks since prior radiotherapy and recovered Surgery - Recovered from any recent surgery Other - At least 3 weeks since prior therapy for endometrial cancer - No other concurrent investigational agents - No prior anticancer therapy that would preclude study participation
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PaulaFracasso, Study Chair, Washington University School of Medicine
Southeast Gynecologic Oncology Associates *Recruiting*
Knoxville, Tennessee, 37917
United States
Recruiting Kenneth Cofer 865-673-9250
CCOP - Carle Cancer Center *Recruiting*
Urbana, Illinois, 61801
United States
Recruiting Kendrith Rowland 217-383-4083
Abington Memorial Hospital *Recruiting*
Abington, Pennsylvania, 19001-3788
United States
Recruiting Parviz Hanjani 215-885-0220
CCOP - Kansas City *Recruiting*
Kansas City, Missouri, 64131
United States
Recruiting Jorge Paradelo 816-823-0555
CCOP - Grand Rapids *Recruiting*
Grand Rapids, Michigan, 49503
United States
Recruiting Kathleen Yost 616-391-1230
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center *Recruiting*
Orange, California, 92868
United States
Recruiting Robert Burger 714-456-7971
CCOP - Kalamazoo *Recruiting*
Kalamazoo, Michigan, 49007-3731
United States
Recruiting Raymond Lord 269-373-7488
Kansas Cancer Institute at the University of Kansas Medical Center *Recruiting*
Kansas City, Kansas, 66160-7357
United States
Recruiting Julia Chapman 913-588-6225
CCOP - Cancer Research for the Ozarks *Recruiting*
Springfield, Missouri, 65807
United States
Recruiting John Goodwin 417-269-4520
MBCCOP - University of Illinois at Chicago *Recruiting*
Chicago, Illinois, 60612
United States
Recruiting Lawrence Feldman 312-335-3614
Ellis Fischel Cancer Center at University of Missouri - Columbia *Recruiting*
Columbia, Missouri, 65203
United States
Recruiting Sara Crowder 573-882-1057
CCOP - Geisinger Clinic and Medical Center *Recruiting*
Danville, Pennsylvania, 17822-2001
United States
Recruiting Nava Siegelmann-Danieli 570-271-6834
CCOP - Columbia River Oncology Program *Recruiting*
Portland, Oregon, 97225
United States
Recruiting Keith Lanier 503-216-6260
New Britain General Hospital *Recruiting*
New Britain, Connecticut, 06052
United States
Recruiting James Hoffman 860-826-1101
CCOP - Central Illinois *Recruiting*
Decatur, Illinois, 62794-9640
United States
Recruiting L. Massad 217-545-8882
CCOP - Marshfield Clinic Research Foundation *Recruiting*
Marshfield, Wisconsin, 54449
United States
Recruiting Anthony Evans 715-389-3101
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Michael Bookman 215-728-2987
CCOP - Metro-Minnesota *Recruiting*
St. Louis Park, Minnesota, 55416
United States
Recruiting Patrick Flynn 952-993-15175
CCOP - Evanston *Recruiting*
Evanston, Illinois, 60201
United States
Recruiting Gershon Locker 847-570-2518
CCOP - Michigan Cancer Research Consortium *Recruiting*
Ann Arbor, Michigan, 48106
United States
Recruiting Philip Stella 734-712-2000
Magee-Womens Hospital *Recruiting*
Pittsburgh, Pennsylvania, 15213-3180
United States
Recruiting Joseph Kelley 412-641-5418
Saint Joseph Regional Medical Center *Recruiting*
South Bend, Indiana, 46617
United States
Recruiting Michael Method 574-237-8010
CCOP - Scott and White Hospital *Recruiting*
Temple, Texas, 76508
United States
Recruiting Lucas Wong 254-724-7048
Mount Carmel West Hospital *Recruiting*
Columbus, Ohio, 43222
United States
Recruiting Luis Vaccarello 614-224-7662
University of Mississippi Medical Center *Recruiting*
Jackson, Mississippi, 39216-4505
United States
Recruiting James Thigpen 601-984-5590
CCOP - Christiana Care Health Services *Recruiting*
Newark, Delaware, 19713
United States
Recruiting Stephen Grubbs 302-623-4100
CCOP - Western Regional, Arizona *Recruiting*
Phoenix, Arizona, 85006-2726
United States
Recruiting David King 602-258-4875
Penn State Cancer Institute at Milton S. Hershey Medical Center *Recruiting*
Hershey, Pennsylvania, 17033-0850
United States
Recruiting George Olt 717-531-8144
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center *Recruiting*
Nashville, Tennessee, 37232-2516
United States
Recruiting Marta Crispens 615-322-2114
CCOP - Missouri Valley Cancer Consortium *Recruiting*
Omaha, Nebraska, 68106
United States
Recruiting James Mailliard 402-280-4364
Additional Information:
Study ID Numbers: CDR0000068235; GOG-0129K
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071929
Other Recurrent Endometrial Cancer Studies:
1. Hormone Therapy With LY353381 Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
2. Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
3. Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
4. Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
5. Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Related Studies:
Other recurrent endometrial cancer Clinical Trials
Other Michigan Clinical Trials
Other Kalamazoo Clinical Trials
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
|
|
|
|
|
|
|
